XBiotech Net Worth
XBiotech Net Worth Breakdown | XBIT |
XBiotech Net Worth Analysis
XBiotech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including XBiotech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of XBiotech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform XBiotech's net worth analysis. One common approach is to calculate XBiotech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares XBiotech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing XBiotech's net worth. This approach calculates the present value of XBiotech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of XBiotech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate XBiotech's net worth. This involves comparing XBiotech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into XBiotech's net worth relative to its peers.
Enterprise Value |
|
To determine if XBiotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding XBiotech's net worth research are outlined below:
| XBiotech appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 300 K. Net Loss for the year was (24.56 M) with profit before overhead, payroll, taxes, and interest of 3.36 M. | |
| XBiotech currently holds about 225.79 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.42. | |
| XBiotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 35.0% of the company outstanding shares are owned by insiders | |
| Latest headline from MacroaxisInsider: Disposition of 12308 shares by Han Queena of XBiotech at 4.16 subject to Rule 16b-3 |
XBiotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in XBiotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to XBiotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of January 2024 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View |
Know XBiotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as XBiotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XBiotech backward and forwards among themselves. XBiotech's institutional investor refers to the entity that pools money to purchase XBiotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 77.7 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 72.5 K | Empowered Funds, Llc | 2024-06-30 | 69.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 58.4 K | Fmr Inc | 2024-09-30 | 29 K | Nuveen Asset Management, Llc | 2024-06-30 | 24.9 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 23.6 K | Rhumbline Advisers | 2024-06-30 | 20.1 K | Citigroup Inc | 2024-09-30 | 14.5 K | Blackrock Inc | 2024-06-30 | 1.1 M | Vanguard Group Inc | 2024-09-30 | 1.1 M |
Follow XBiotech's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 231.98 M.Market Cap |
|
Project XBiotech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.11) | (0.11) | |
| Return On Capital Employed | (0.17) | (0.18) | |
| Return On Assets | (0.11) | (0.11) | |
| Return On Equity | (0.11) | (0.12) |
When accessing XBiotech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures XBiotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of XBiotech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in XBiotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of XBiotech. Check XBiotech's Beneish M Score to see the likelihood of XBiotech's management manipulating its earnings.
Evaluate XBiotech's management efficiency
XBiotech has return on total asset (ROA) of (0.1203) % which means that it has lost $0.1203 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1575) %, meaning that it created substantial loss on money invested by shareholders. XBiotech's management efficiency ratios could be used to measure how well XBiotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.11 in 2024. Return On Capital Employed is likely to drop to -0.18 in 2024. Total Current Liabilities is likely to gain to about 9.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 209.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.22 | 4.35 | |
| Tangible Book Value Per Share | 7.22 | 4.48 | |
| Enterprise Value Over EBITDA | 2.20 | 2.31 | |
| Price Book Value Ratio | 0.55 | 0.53 | |
| Enterprise Value Multiple | 2.20 | 2.31 | |
| Price Fair Value | 0.55 | 0.53 | |
| Enterprise Value | -58 M | -55.1 M |
The operational strategies employed by XBiotech management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 24.051 | Revenue 300 K | Quarterly Revenue Growth (0.93) | Revenue Per Share 0.01 | Return On Equity (0.16) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific XBiotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on XBiotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases XBiotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
XBiotech Corporate Filings
10Q | 13th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 21st of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 20th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 1st of May 2024 An amendment to a previously filed Form 10-K | ViewVerify |
XBiotech Earnings per Share Projection vs Actual
XBiotech Corporate Management
| Benjamn Guzmn | Sr Fin | Profile | |
| Angela Hu | Principal Finance | Profile | |
| Lisa Simard | Inc USA | Profile | |
| Sushma Shivaswamy | Chief Officer | Profile | |
| BA CGA | VP Sec | Profile |
Already Invested in XBiotech?
The danger of trading XBiotech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XBiotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XBiotech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XBiotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.